119 related articles for article (PubMed ID: 11345533)
1. Flow cytometric evaluation of antiviral agents against human herpesvirus 6.
Amjad M; Gillespie MA; Carlson RM; Karim MR
Microbiol Immunol; 2001; 45(3):233-40. PubMed ID: 11345533
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis.
Manichanh C; Grenot P; Gautheret-Dejean A; Debré P; Huraux JM; Agut H
Cytometry; 2000 Jun; 40(2):135-40. PubMed ID: 10805933
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antiviral compounds against human herpesvirus 6 and 7.
Yoshida M; Yamada M; Tsukazaki T; Chatterjee S; Lakeman FD; Nii S; Whitley RJ
Antiviral Res; 1998 Dec; 40(1-2):73-84. PubMed ID: 9864048
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6.
Reymen D; Naesens L; Balzarini J; Holý A; Dvoráková H; De Clercq E
Antiviral Res; 1995 Dec; 28(4):343-57. PubMed ID: 8669893
[TBL] [Abstract][Full Text] [Related]
5. Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry.
Long MC; Bidanset DJ; Williams SL; Kushner NL; Kern ER
Antiviral Res; 2003 Apr; 58(2):149-57. PubMed ID: 12742575
[TBL] [Abstract][Full Text] [Related]
6. A method for detection of HHV-6 antigens and its use for evaluating antiviral drugs.
Yoshida M; Yamada M; Chatterjee S; Lakeman F; Nii S; Whitley RJ
J Virol Methods; 1996 Apr; 58(1-2):137-43. PubMed ID: 8783159
[TBL] [Abstract][Full Text] [Related]
7. Selective activity of various antiviral compounds against HHV-7 infection.
Zhang Y; Schols D; De Clercq E
Antiviral Res; 1999 Aug; 43(1):23-35. PubMed ID: 10480261
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of foscarnet and acyclovir on reproduction of human herpesvirus 6 in cell culture].
Mel'nichenko AV; L'vov ND; Galegov GA
Antibiot Khimioter; 2009; 54(1-2):17-9. PubMed ID: 19499712
[TBL] [Abstract][Full Text] [Related]
9. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet.
Pavić I; Hartmann A; Zimmermann A; Michel D; Hampl W; Schleyer I; Mertens T
Antimicrob Agents Chemother; 1997 Dec; 41(12):2686-92. PubMed ID: 9420039
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.
Maggs DJ; Clarke HE
Am J Vet Res; 2004 Apr; 65(4):399-403. PubMed ID: 15077679
[TBL] [Abstract][Full Text] [Related]
13. Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells.
Yao K; Hoest C; Rashti F; Schott TC; Jacobson S
J Clin Virol; 2009 Sep; 46(1):10-4. PubMed ID: 19524486
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Andrei G; Snoeck R; Neyts J; Sandvold ML; Myhren F; De Clercq E
Antiviral Res; 2000 Mar; 45(3):157-67. PubMed ID: 10771080
[TBL] [Abstract][Full Text] [Related]
15. Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance.
Lipson SM; Soni M; Biondo FX; Shepp DH; Kaplan MH; Sun T
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):123-9. PubMed ID: 9294702
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
17. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient.
Isegawa Y; Hara J; Amo K; Osugi Y; Takemoto M; Yamanishi K; Fukunaga R; Shibata M; Ohshima A; Horiguchi Y; Sugimoto N
J Clin Virol; 2009 Jan; 44(1):15-9. PubMed ID: 18952495
[TBL] [Abstract][Full Text] [Related]
18. [Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Takahashi K
Nihon Rinsho; 1998 Jan; 56(1):140-4. PubMed ID: 9465679
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antiviral compounds in human herpesvirus-6-infected glial cells.
Akhyani N; Fotheringham J; Yao K; Rashti F; Jacobson S
J Neurovirol; 2006 Aug; 12(4):284-93. PubMed ID: 16966219
[TBL] [Abstract][Full Text] [Related]
20. Modifications on the heterocyclic base of ganciclovir, penciclovir, acyclovir - syntheses and antiviral properties.
Chuchkov K; Chayrov R; Hinkov A; Todorov D; Shishkova K; Stankova IG
Nucleosides Nucleotides Nucleic Acids; 2020; 39(7):979-990. PubMed ID: 32312162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
